The U.S. Food and Drug Administration (FDA) has granted Arjuna Natural Extracts Ltd. a U.S. patent for the company's turmeric extract formulation, BCM-95 Curcumin, which is expected to become a treatment for patients suffering from Alzheimer's disease. The patent number 8859020 describes the drugs's combination of beneficial curcuminoids and turmeric essential oil present in BCM-95, and its enhanced absorption and bioavailability.
BCM-95 Curcumin has been revealed to be highly beneficial in preventing the progression of cognitive decline and reducing amyloid beta plaques, which is one of the largest known causes for the development of Alzheimer's. In addition, it is also efficient in increasing the levels of vitamin E and enhancing curcumin levels in blood. The results were demonstrated by a series of human clinical trials conducted with Alzheimer's patients, by researchers at the Chinese University of Hong Kong and led by Professor Larry Baum in 2008.
"These research findings will open a new world of hope to the millions battling Alzheimer's every day, as they will now have a natural and safe alternative for addressing Alzheimer's," said the Joint Managing Director at Arjuna Natural Extracts Ltd. and inventor of BCM-95,